Contact Us    |      Join    |

"The Voice of Oncology in Massachusetts"

CMS has granted ELREXFIO (elranatamab-bccm) injection pass-through status for Hospital OPPS: New C-Code

January 22, 2024 6:46 PM | Katy Monaco (Administrator)

Effective for dates of service on or after January 1, 2024, the Centers for Medicare and Medicaid Services (CMS) has granted ELREXFIO (elranatamab-bccm) injection pass-through status for Hospital OPPS and has assigned the following Healthcare Common Procedure Coding System (HCPCS)* C-Code:

C9165 - Injection, elranatamab-bcmm, 1 mg

We are respectfully requesting that you update your membership about this important coding change for ELREXFIO (elranatamab-bccm).

Please click on the links to see the full Prescribing Information, including BOXED WARNING, and Medication Guide for ELREXFIO.


ADDRESS

860 Winter Street, Waltham, MA, 02451

CONTACT US

tel: 781.434.7329

msco@mms.org

Massachusetts Society of Clinical Oncologists ©2024

Powered by Wild Apricot Membership Software